Nasdaq · CIK 0000832489
GOVX GeoVax Labs, Inc.
Insider trading from SEC Form 4. Last filing Jun 22, 2026. Close $0.28 on Oct 9, 2026, 0% from the 52-week low and -98% from the high.
In brief
GeoVax Labs, Inc. (GOVX) has 31 SEC Form 4 filings on file from 11 insiders, the latest filed on Jun 22, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
9 open-market trades have been scored at GOVX. The newest: John N Spencer Jr (director) bought $5,498 of stock on Oct 17, 2025, filed Oct 20, 2025, scored 33 (weak). The largest of the 9 shown: David A Dodd (President, CEO) bought $20k on Feb 21, 2024, scored 61 (notable). 4 insiders bought within 14 days of each other around Apr 10, 2025.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at GeoVax Labs, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 33Weak | John N Spencer Jr director buy | $5,498 10,000 shares | +88% | +17% from low-83% from high | |
| 29Weak | Kelly T. McKee Jr. Chief Medical Officer buy | $742 1,107 shares | +46% | +40% from low-79% from high | |
| 58Moderate | John N Spencer Jr director buy | $9,800 10,000 shares | +713% | 0% from low-71% from high | |
| 58Moderate | John W. Sharkey VP, Business Development buy | $5,940 6,000 shares | +3141% | 0% from low-71% from high | |
| 64Notable | David A Dodd President, CEO buy | $11k 10,000 shares | +38% | +2% from low-67% from high | |
| 65Notable | Mark Reynolds CFO buy | $7,343 6,800 shares | +94% | 0% from low-67% from high | |
| 61Notable | David A Dodd President, CEO buy | $20k 8,729 shares | +88% | 0% from low-82% from high | |
| 54Moderate | Mark Reynolds CFO buy | $5,540 2,000 shares | +38% | +2% from low-81% from high | |
| 29Weak | Kelly T. McKee Jr. Chief Medical Officer buy | $2,500 6,944 shares | +24% | +22% from low-67% from high |
Transactions
Every row filed, 32 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 17, 2026 | David A Dodd President, CEO | AGrant or award Stock Optionderivative | +29,300 | $0.00 | $0 | 29,300 | Jun 22, 2026 |
| Jun 17, 2026 | Randal D Chase director | AGrant or award Stock Optionderivative | +6,000 | $0.00 | $0 | 6,000 | Jun 22, 2026 |
| Jun 17, 2026 | John N Spencer Jr director | AGrant or award Stock Optionderivative | +6,000 | $0.00 | $0 | 6,000 | Jun 22, 2026 |
| Jun 17, 2026 | Jayne Morgan director | AGrant or award Stock Optionderivative | +6,000 | $0.00 | $0 | 6,000 | Jun 22, 2026 |
| Jun 17, 2026 | Robert T McNally director | AGrant or award Stock Optionderivative | +6,000 | $0.00 | $0 | 6,000 | Jun 22, 2026 |
| Jun 17, 2026 | Nicole Lemerond director | AGrant or award Stock Optionderivative | +6,000 | $0.00 | $0 | 6,000 | Jun 22, 2026 |
| Jun 17, 2026 | Dean G Kollintzas director | AGrant or award Stock Optionderivative | +6,000 | $0.00 | $0 | 6,000 | Jun 22, 2026 |
| Jun 17, 2026 | John W. Sharkey VP, Business Development | AGrant or award Stock Optionderivative | +17,600 | $0.00 | $0 | 17,600 | Jun 22, 2026 |
| Jun 17, 2026 | Mark Reynolds CFO | AGrant or award Stock Optionderivative | +17,600 | $0.00 | $0 | 17,600 | Jun 22, 2026 |
| Jun 17, 2026 | Mark J Newman Chief Scientific Officer | AGrant or award Stock Optionderivative | +17,600 | $0.00 | $0 | 17,600 | Jun 22, 2026 |
| Jun 17, 2026 | Kelly T. McKee Jr. Chief Medical Officer | AGrant or award Stock Optionderivative | +17,600 | $0.00 | $0 | 17,600 | Jun 22, 2026 |
| Oct 17, 2025 | John N Spencer Jr director | POpen-market purchase Common Stock | +10,000 | $0.55 | $5,498 | 21,402 | Oct 20, 2025 |
| Aug 7, 2025 | Kelly T. McKee Jr. Chief Medical Officer | POpen-market purchase Common Stock | +1,107 | $0.67 | $742 | 3,494 | Aug 8, 2025 |
| Jun 5, 2025 | Nicole Lemerond director | AGrant or award Stock Optionderivative | +10,000 | $0.00 | $0 | 10,000 | Jun 6, 2025 |
| Jun 5, 2025 | Dean G Kollintzas director | AGrant or award Stock Optionderivative | +10,000 | $0.00 | $0 | 10,000 | Jun 6, 2025 |
| Jun 5, 2025 | Robert T McNally director | AGrant or award Stock Optionderivative | +10,000 | $0.00 | $0 | 10,000 | Jun 6, 2025 |
| Jun 5, 2025 | John W. Sharkey VP, Business Development | AGrant or award Stock Optionderivative | +70,000 | $0.00 | $0 | 70,000 | Jun 6, 2025 |
| Jun 5, 2025 | Jayne Morgan director | AGrant or award Stock Optionderivative | +10,000 | $0.00 | $0 | 10,000 | Jun 6, 2025 |
| Jun 5, 2025 | John N Spencer Jr director | AGrant or award Stock Optionderivative | +10,000 | $0.00 | $0 | 10,000 | Jun 6, 2025 |
| Jun 5, 2025 | Mark J Newman Chief Scientific Officer | AGrant or award Stock Optionderivative | +70,000 | $0.00 | $0 | 70,000 | Jun 6, 2025 |
| Jun 5, 2025 | Kelly T. McKee Jr. Chief Medical Officer | AGrant or award Stock Optionderivative | +70,000 | $0.00 | $0 | 70,000 | Jun 6, 2025 |
| Jun 5, 2025 | Mark Reynolds CFO | AGrant or award Stock Optionderivative | +70,000 | $0.00 | $0 | 70,000 | Jun 6, 2025 |
| Jun 5, 2025 | David A Dodd President, CEO | AGrant or award Stock Optionderivative | +185,500 | $0.00 | $0 | 185,500 | Jun 6, 2025 |
| Jun 5, 2025 | Randal D Chase director | AGrant or award Stock Optionderivative | +10,000 | $0.00 | $0 | 10,000 | Jun 6, 2025 |
| Apr 10, 2025 | John N Spencer Jr director | POpen-market purchase Common Stock | +10,000 | $0.98 | $9,800 | 11,402 | Apr 11, 2025 |
| Apr 10, 2025 | John W. Sharkey VP, Business Development | POpen-market purchase Common Stock | +6,000 | $0.99 | $5,940 | 6,191 | Apr 10, 2025 |
| Apr 1, 2025 | David A Dodd President, CEO | POpen-market purchase Common Stock | +10,000 | $1.08 | $11k | 36,661 | Apr 1, 2025 |
| Mar 31, 2025 | Mark Reynolds CFO | POpen-market purchase Common Stock | +6,800 | $1.08 | $7,343 | 14,013 | Mar 31, 2025 |
| Feb 21, 2024 | David A Dodd President, CEO | POpen-market purchase Common Stock | +520 | $2.15 | $1,118 | 10,452 | Feb 22, 2024 |
| Feb 22, 2024 | David A Dodd President, CEO | POpen-market purchase Common Stock | +8,209 | $2.27 | $19k | 18,661 | Feb 22, 2024 |
| Feb 7, 2024 | Mark Reynolds CFO | POpen-market purchase Common Stock | +2,000 | $2.77 | $5,540 | 7,213 | Feb 7, 2024 |
| Dec 22, 2023 | Kelly T. McKee Jr. Chief Medical Officer | POpen-market purchase Common Stock | +6,944 | $0.36 | $2,500 | 35,782 | Dec 26, 2023 |
Insiders
Everyone who has filed a Form 4 here.
- Randal D Chasedirector
- David A DoddPresident, CEO
- Dean G Kollintzasdirector
- Nicole Lemeronddirector
- Robert T McNallydirector
- Kelly T. McKee Jr.Chief Medical Officer
- Jayne Morgandirector
- Mark J NewmanChief Scientific Officer
- Mark ReynoldsCFO
- John N Spencer Jrdirector
- John W. SharkeyVP, Business Development
Questions about GOVX
Answered from the filings on this page, as of the latest one.
Are insiders buying GOVX?
No. In the last 90 days no insider at GeoVax Labs, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade GOVX on the open market?
John N Spencer Jr (director) bought $5,498 of GOVX on Oct 17, 2025 and filed the Form 4 on Oct 20, 2025. InsiderTell scored 33 (weak).
How many insiders file Form 4 at GeoVax Labs, Inc.?
11 people have filed a Form 4 at GeoVax Labs, Inc., among them Randal D Chase (director), David A Dodd (President, CEO), Dean G Kollintzas (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.